Axitinib: all 159 studies that test it

Page 1 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingNCT07816770Phase 2
• TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07776717Phase 2
• SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaRecruitingNCT07744932Phase 2
• Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyRecruitingNCT07516132Phase 3
• Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell CarcinomaNot yet recruitingNCT07500831Not applicable
• An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07469683Phase 2
• Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCCRecruitingNCT07172386Phase 2
• Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingNCT07159191Phase 2
• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingNCT07123090Phase 2
• SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCCRecruitingNCT06889649Phase 2
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
• CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
• Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaNot yet recruitingNCT06279403Phase 2
• Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingNCT06211114Phase 2
• The Efficacy and Safety of KN046 Combined With AxitinibRecruitingNCT06020352Phase 2/3
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingNCT05969496Phase 2
• Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsRecruitingNCT05817903Phase 2
• Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingNCT05768464Phase 2
• Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingNCT05738694Phase 3
• Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingNCT05384496Phase 2
• A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerNot yet recruitingNCT04958473Phase 2
• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingNCT04693468Phase 1
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaTerminatedNCT05249569Phase 2Results posted
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaCompletedNCT04493203Phase 2Results posted
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted
• Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal CancerCompletedNCT04355156Phase 2Results posted
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03990571Phase 2Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionCompletedNCT03494816Phase 2Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)CompletedNCT03289533Phase 1Results posted
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedNCT02853331Phase 3Results posted
• Expansion Trial for Axitinib In Head And Neck CancerCompletedNCT02762513Phase 2Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaCompletedNCT02667886Phase 1/2Results posted
• Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue SarcomasCompletedNCT02636725Phase 2Results posted
• Axitinib Given on an Individualized Schedule for Metastatic Renal Cell CancerCompletedNCT02579811Phase 2Results posted
• Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
• SLM + Axitinib for Clear Cell RCCCompletedNCT02535533Phase 1/2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results posted
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT02129647Phase 2Results posted
• A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid TumorsCompletedNCT01999972Phase 1Results posted
• Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompletedNCT01967576Phase 2Results posted
• Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell CarcinomaTerminatedNCT01806064Phase 1/2Results posted
• Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine CarcinomasCompletedNCT01744249Phase 2/3Results posted
• Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell CarcinomaTerminatedNCT01727336Phase 2Results posted
• A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for NephrectomyCompletedNCT01693822Phase 2Results posted
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell CarcinomaTerminatedNCT01649180Phase 2Results posted
• Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk PatientsTerminatedNCT01599754Phase 3Results posted
• Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT01558661Phase 2Results posted
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01533948Phase 2Results posted
• Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) PatientsTerminatedNCT01508117Phase 2Results posted
• A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)CompletedNCT01490866Phase 2Results posted
• Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck CancerCompletedNCT01469546Phase 2Results posted
• First In Human, Phase 1 Study of AG013736 In Patients With Solid TumorsCompletedNCT01469052Phase 1Results posted
• A Study of Axitinib in Advanced Carcinoid TumorsCompletedNCT01435122Phase 2Results posted
• Axitinib Before Surgery in Treating Patients With High-Risk Prostate CancerCompletedNCT01385059Phase 2Results posted
• Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant MelanomaCompletedNCT01321437Phase 2Results posted
• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)CompletedNCT01263769Phase 2Results posted
• Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerCompletedNCT01255137Phase 2Results posted
• Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Phase 2Results posted
• A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in MelanomaCompletedNCT01174238Phase 2Results posted
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell CancerCompletedNCT00920816Phase 3Results posted
• Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric CancerCompletedNCT00842244Phase 1Results posted
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney CancerCompletedNCT00835978Phase 2Results posted
• Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical TrialsCompletedNCT00828919Not applicableResults posted
• Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung CancerCompletedNCT00768755Phase 1/2Results posted
• Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung CancerCompletedNCT00735904Phase 2Results posted
• A Study In Patients With Advanced Solid TumorCompletedNCT00726752Phase 1Results posted
• Evaluation Of Hepatic Impairment On AG-013736 PharmacokineticsCompletedNCT00692341Phase 1Results posted
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerCompletedNCT00678392Phase 3Results posted
• A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenCompletedNCT00615056Phase 2Results posted
• A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.CompletedNCT00600821Phase 2Results posted
• Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)CompletedNCT00569946Phase 2Results posted
• Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.CompletedNCT00471146Phase 3Results posted
• Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal CancerCompletedNCT00460603Phase 1/2Results posted
• Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid TumorCompletedNCT00454649Phase 1Results posted
• Study Of AG-013736 (Axitinib) In Patients With Advanced Solid TumorsCompletedNCT00447005Phase 1Results posted
• Study Of AG-013736 In Patients With 131I-Refractory Thyroid CancerCompletedNCT00389441Phase 2Results posted
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell CancerCompletedNCT00282048Phase 2Results posted
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic CancerCompletedNCT00219557Phase 2Results posted
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic MelanomaCompletedNCT00094107Phase 2Results posted
• Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00094094Phase 2Results posted
• Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid CancerCompletedNCT00094055Phase 2Results posted
• AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast CancerCompletedNCT00076024Phase 1/2Results posted
• AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)CompletedNCT00071006Phase 2Results posted
• Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCCSuspendedNCT06860386Phase 2
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationActive, not recruitingNCT06495918Phase 3
• Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsCompletedNCT05904730Phase 1
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell CarcinomaActive, not recruitingNCT05808608Phase 1/2
• Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic RetinopathyActive, not recruitingNCT05695417Phase 1
• Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT05420220Phase 2

← Axitinib overview